



## SCIENTIFIC PROGRAMME

Session details

e-Poster Walk  
e-Poster Walk Session 09: Schizophrenia part 1

e-Poster Area Date: Sunday 29th e-Poster Walk From: 12:30 To: 13:15

**RISK AND PROTECTIVE FACTORS FOR RELAPSE IN OUTPATIENTS WITH SCHIZOPHRENIA.**  
I Bellido<sup>1</sup>, C Lopez<sup>2</sup>, MV Bellido<sup>3</sup>, Blanco E<sup>3</sup>, A Gomez-Luque<sup>1</sup>  
D. Pharmacology-Clinical Therapeutics<sup>1</sup> and S. Psychiatry<sup>2</sup>. School of Medicine, Malaga, Spain.  
ibellido@uma.es

We aim to determine risk and protective factors influencing relapse incidence in outpatient with schizophrenia.

A longitudinal, observational study was done with outpatients with schizophrenia (F20) or schizoaffective disorder (F25)(DMS-IV and ICD-10), without hospitalization during the previous 6 months. The patients were consecutively included into the study to received oral (O-A) or long-acting injectable (depot-A) antipsychotics. Clinical stage evolution, compliance, efficacy and safety assessments (including PANSS, CGI-SSI, hospitalization rates, and adverse events) were recorded before and after 6 and 12 months of treatment.

Results: 60 outpatients (aged  $34.5 \pm 8.9$ , male 73%), 75% schizophrenia and 25% schizoaffective disorder diagnosis, 68.3% fewer than 15 years of schizophrenia evolution, 76.7% fewer than 5 times previous hospitalizations were treated with O-A (41.7%) or depot-A (58.3%) antipsychotics for at least one year. Depot-A treated patients showed a significant higher compliance compared to O-A patients during the all following time, lower PANSS (total, positive and negative) scores and CGI-SSI score ( $p < 0.01$ ), and a delayed relapse incidence and re-hospitalization to more than 1 year in the 48% of patients (relapse % depot/% oral) after 6 months 22.9%/52.0%, and after 12 months 48.6%/4.0%.

Conclusion: There were protective factors which delayed relapse incidence in schizophrenia: Use of sustained-release preparations, family support. There were risk factors for occurrence of relapse in schizophrenia: cocaine, heroin and alcohol consumption, absence of family support, greater severity of patients assessed through CGI-SI, male sex, age older than 25 years and long-term evolution of the disorder. Cannabis use did not affect the incidence of relapse.

### Presenting author:

Name: Bellido Inmaculada

Ordinary mail address: Department of Pharmacology and Clinical Therapeutics, School of Medicine. Campus de Teatinos. Bulevar Louis Pasteur, n° 32, Malaga, 29071, Spain

Phone: 34952131566

Fax number 34952131568

E-mail address: ibellido@uma.es

Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech.